Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CETRORELIX ACETATE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) antagonist. Competitively blocks Gn RH receptors on pituitary gonadotropes, inhibiting secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
250 mcg subcutaneously once daily, starting on day 7 of ovarian stimulation and continuing until the day of h CG administration. Alternatively, a single 3 mg subcutaneous dose on day 7 of stimulation if h CG is given on day 9.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life: ~7-9 hours in healthy adults; prolonged to ~14-30 hours in patients with hepatic or renal impairment (clinical significance: no dose adjustment needed for mild-to-moderate renal or hepatic impairment, but caution in severe cases due to potential accumulation).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Metabolized via peptidolysis; not significantly metabolized by cytochrome P450 enzymes.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal (excreted unchanged in urine ~42% within 24 hours; total urinary recovery ~66-69% over 8 days); biliary/fecal elimination accounts for <5%.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
86-96% bound to albumin (alpha-1-acid glycoprotein binding not significant).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Apparent Vd: 1.14 L/kg (range 0.8–1.4 L/kg), indicating distribution primarily into extracellular fluid; not extensively tissue-bound.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Subcutaneous: ~85% (absolute bioavailability).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Insufficient data for severe impairment (GFR <30 m L/min); use with caution.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C); use with caution.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Not indicated in pediatric patients (safety and efficacy not established).
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
No specific dose adjustment; limited experience in women >65 years. Use with caution due to reduced renal and hepatic function.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None.
None.
Hypersensitivity reactions including anaphylaxis and urticaria.,Ovarian hyperstimulation syndrome (OHSS) due to gonadotropin therapy.,Pregnancy category X: contraindicated in pregnancy.,May cause fetal harm if administered during pregnancy.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to cetrorelix acetate, mannitol, or any component.,Pregnancy and lactation.,Postmenopausal women.,Severe hepatic or renal impairment (safety not established).
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions. No dietary restrictions required.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Category X. Risk of congenital anomalies if pregnancy occurs. Avoid use during pregnancy; confirm negative pregnancy test before initiation. First trimester: No data; theoretical risk due to hormonal antagonism. Second and third trimesters: Not indicated for use; may interfere with pregnancy maintenance.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Not recommended during breastfeeding. M/P ratio unknown; cetrorelix is likely excreted in milk based on molecular weight; potential for adverse effects in the infant, including hormonal disruption.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Contraindicated in pregnancy; no dose adjustment recommended. Use only in non-pregnant patients. Pharmacokinetic changes in pregnancy unknown; drug not intended for use during gestation.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Administer subcutaneously in the lower abdominal wall. Rotate injection sites. Reconstitute with 1 m L of sterile water for injection or provided diluent; use immediately after reconstitution. Monitor for ovarian hyperstimulation syndrome (OHSS), especially in patients with polycystic ovary syndrome. Cetrorelix can cause transient injection site reactions. It is contraindicated in pregnancy and during lactation.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Cetrorelix is used to prevent premature ovulation during fertility treatments.,Inject the medication exactly as prescribed, usually once daily in the abdomen.,Rotate injection sites and do not inject into irritated or bruised skin.,Do not skip doses; if a dose is missed, contact your healthcare provider.,Report any symptoms of OHSS such as severe pelvic pain, nausea, vomiting, or sudden weight gain.,This drug is not for use during pregnancy; inform your doctor if you think you are pregnant.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
No interactions on record
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CETRORELIX ACETATE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
CETRORELIX ACETATE is a GnRH antagonist that works by Gonadotropin-releasing hormone (Gn RH) antagonist. Competitively blocks Gn RH receptors on pituitary gonadotropes, inhibiting secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CETRORELIX ACETATE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CETRORELIX ACETATE is: 250 mcg subcutaneously once daily, starting on day 7 of ovarian stimulation and continuing until the day of h CG administration. Alternatively, a single 3 mg subcutaneous dose on day 7 of stimulation if h CG is given on day 9.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CETRORELIX ACETATE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CETRORELIX ACETATE is classified as Category C. Category X. Risk of congenital anomalies if pregnancy occurs. Avoid use during pregnancy; confirm negative pregnancy test before initiation. First trimester: No data; theoretical r. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.